Ocular Surgery News
Allegro Ophthalmics has completed enrollment of a phase 1b/2a study of the impact of its integrin peptide therapy on wet age-related macular degeneration, according to a company news release. In addition, Allegro has begun a second study of the therapy’s impact on diabetic macular edema.